EBITDA: Income before interest, taxes, depreciation and amortization.
Anebulo Pharmaceuticals, Inc. (ANEB) had EBITDA of $-2.60M for the most recently reported fiscal quarter, ending 2025-12-31.
| Income Statement Financials | |
-- |
|
$-2.00M |
|
-- |
|
-- |
|
$2.62M |
|
$-2.62M |
|
$0.62M |
|
$-2.00M |
|
$-2.00M |
|
$-2.00M |
|
$-2.00M |
|
$-2.00M |
|
$-2.00M |
|
$-2.62M |
|
|
EBITDA |
$-2.60M |
41.09M |
|
41.09M |
|
$-0.05 |
|
$-0.05 |
|
| Balance Sheet Financials | |
$9.27M |
|
-- |
|
$0.15M |
|
$9.42M |
|
$1.49M |
|
-- |
|
-- |
|
$1.49M |
|
$7.94M |
|
$7.94M |
|
$7.94M |
|
41.09M |
|
| Cash Flow Statement Financials | |
$-2.59M |
|
-- |
|
-- |
|
$11.63M |
|
$9.04M |
|
$-2.59M |
|
$0.44M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
6.24 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
$-2.59M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-25.19% |
|
-25.19% |
|
-21.22% |
|
-25.19% |
|
$0.19 |
|
$-0.06 |
|
$-0.06 |
|